Syntara Limited (PMXSF) Discusses 2026 Clinical Pipeline Outlook and Anticipated Trial Updates Transcript

Matthew Wright

Thanks for standing by, and welcome to the Syntara 2026 outlook webinar and Q&A. [Operator Instructions] On the webinar from Syntara today, we have CEO, Gary Phillips, and he’s joined by Non-Executive Director, Hashan De Silva, whose from KPRX, is also one of Syntara’s largest shareholders.

To begin, I’ll hand it over to Gary. Please go ahead.

Gary Phillips
CEO, MD & Director

Thanks, Matt, and welcome to all of you, and thank you for sparing some time this morning to listen to us. We thought about the year ahead, and I think Syntara stands out amongst its peer group as having a really busy ’26 with a pipeline of assets which are going to deliver near constant flow of news as we go through the year. So we thought we’d start the year by actually giving a chance for shareholders to ask questions about that pipeline and for us to go in a bit more granularity about that news flow, what to expect and when as we head through the year.

I’m delighted that Hashan has joined me today. Hashan sits on the Board with me at Syntara, so he’s well across all of the operational issues of the company and the strategy going forward as well, as Matt said, being one of our largest shareholders as well. So we go back — Hashan, and I go back a long way to the time when he was in Karst Peak, originally looking at us as an analyst. So he’s been on the journey with me as well. And I think having his perspective on the call gives an opportunity for